Healthcare - Today Stories

Artrya, in collaboration with the University of Western Australia (UWA) and clinical partners, has unveiled a novel AI‑driven calcium scoring tool—CAC‑DAD—aimed at enhancing heart attack risk prediction. Unlike the traditional Agatston coronary calcium score, which solely measures calcified plaque, CAC‑DAD factors in the location and density of each lesion. It assigns lower risk to dense, stable plaques and higher risk to those near the artery’s origin—addressing key limitations of existing models . Fully automated, CAC‑DAD quickly processes CT scans with a one‑click interface and outperforms the Agatston score in predicting cardiac events in vulnerable patients, particularly around the time of surgery. Early studies demonstrate that combining both scores further enhances diagnostic accura…

Merck (known as MSD outside of the US and Canada) has announced plans to acquire London-based Verona Pharma for approximately $10 billion, aiming to bolster its respiratory treatment offerings. The acquisition centers around Verona's flagship drug, Ohtuvayre, an inhaled, non-steroidal therapy for chronic obstructive pulmonary disease (COPD), approved by the U.S. FDA in June 2024. Since its U.S. launch in August 2024, Ohtuvayre has generated significant sales, contributing over 96% of Verona's Q1 2025 revenue of $76 million.  Merck will pay $107 per American Depository Share, representing a 23% premium over Verona's recent NASDAQ closing price. This move aligns with Merck's strategy to diversify its portfolio ahead of the anticipated 2028 patent expiration of its cancer drug, Keytruda. The…

Announced as part of the government’s 10 Year Health Plan and Plan for Change, the NHS has proposed an 'innovator passport' to streamline the nationwide adoption of medical technologies. This initiative addresses the current system where each of the 215 NHS trusts must individually assess and approve new technologies, leading to administrative inefficiencies. Under the new scheme, once a technology is approved by one NHS trust, it can be adopted by others without redundant evaluations. This change aims to reduce bureaucracy, cut costs, and ensure patients across the UK have equitable access to life-saving innovations. The 'innovator passport' is part of a broader 10-year plan to modernize the NHS, improve patient care, and support the UK's life sciences sector. Health Secretary Wes Streeti…

GSK has partnered with IT services provider adesso to develop DREAM (Digital Reminders for Adherence of Medicines and Vaccines), a digital solution designed to help patients stay on track with medication and vaccination schedules. Originally launched in five pilot markets, DREAM now operates in 23 countries, including the UK, Spain, and Italy. The system delivers personalised, user-friendly reminders to patients, addressing a key healthcare challenge: improving treatment adherence. DREAM was developed with scalability in mind, allowing it to meet regulatory needs across multiple global markets. GSK praised adesso’s agile, committed approach and technological expertise, which helped bring DREAM to life. The collaboration has been ongoing for 18 months and continues to expand, laying the gro…

The University of Hull is establishing a £48m internationally leading translational wound research centre in East Yorkshire.  With a consortium of industry partners, the Wound Innovation Centre (WIC) will be at the forefront of global wound research. Research carried out at the centre will transform the quality of life for those impacted by chronic wounds.  The University has been awarded £16m from the UK Research Partnership Investment Fund. The centre will be match funded by industry partners including Polaroid Therapeutics (PTx) and Reckitt, creating a £48m research facility in East Yorkshire.  Currently the NHS spends approximately £8.3 billion per year on wound care, more than both obesity and cancer. There is a real and increasing need for effective wound care treatment, regionally,…

21 May 2025 – Ramsey, Isle of Man – Juvenescence Ltd., a clinical-stage biotech leveraging AI to target age-related diseases, has announced the successful first close of its Series B-1 financing round, raising $76 million. The round was led by Abu Dhabi-based M42, which also enters a strategic partnership with Juvenescence to advance AI-driven therapeutics. The fresh capital will propel Juvenescence’s pipeline of age-related disease therapies into later-stage clinical trials, with the second tranche of the Series B-1 round expected to close in Q3 2025. This financing follows the announcement of a landmark collaboration between Juvenescence and M42, aimed at establishing a cutting-edge drug development hub in Abu Dhabi. The initiative will merge M42’s capabilities in digital health, genomic…

Aviva Capital Partners (“ACP”), Aviva’s in-house capital unit that invests in a range of infrastructure and real estate projects, and mixed-use developer Socius have unveiled plans for a new £1 billion development to create the world’s leading centre for cancer research and treatment in Sutton, London.  A planning application has been submitted to London Borough of Sutton for the development which will be delivered on a 12-acre site at the London Cancer Hub, adjacent to The Institute of Cancer Research, London, one of the world’s leading cancer research organisations, and The Royal Marsden NHS Foundation Trust’s Sutton site, Europe’s leading centre for cancer treatment. Working with London Borough of Sutton as the landowner, ACP and Socius plan to deliver c. 1 million sq ft of state-of-the…

Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart, Abbott continues to pursue technologies to revolutionize care for people with slow or irregular heart rhythms ABBOTT PARK, Ill., Dec. 17, 2024 ­­­/PRNewswire/ -- Abbott (NYSE: ABT) today announced the successful completion of the world's first in-human leadless left bundle branch area pacing (LBBAP) procedures using the company's investigational AVEIR™…

Abbott's world-leading1 FreeStyle Libre 2 and 3 systems for people living with diabetes are now the only continuous glucose monitoring sensors 2 in the U.S. that users do not need to remove during common imaging procedures like X-rays, CT scans and MRIs* ABBOTT PARK, Ill. – Oct. 30, 2024 – Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) cleared the removal of the imaging contraindication, making Abbott’s systems the first and only patient-applied continuous glucose monitoring (CGM) sensors approved for these screenings. People who use FreeStyle Libre 2 and 3 systems rely on their CGM sensors to make important decisions about their diabetes, inc…

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic brands to life, Opella poised to ignite new bold development journey Sanofi to become a focused science-driven biopharma delivering innovative medicines and vaccines to patients Sanofi 2024 business EPS guidance upgraded today Paris, October 21, 2024. Sanofi and CD&R announce today a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella. This new step in Opella’s journey paves the way for the creation o…

Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration clearance, begins commercial launch ABBOTT PARK, Ill., Oct. 10, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt™ PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), which will be used in the treatment of pati…

Stryker (NYSE: SYK) announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. “We welcome the care.ai team to Stryker and look forward to working together to accelerate our digital vision to provide customers with real-time, smart and connected decision-making tools that can enhance the lives of caregivers and their patients,” stated Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. The acquisition will strengthen Stryker’s growing healthcare IT offering and wirelessly connected medical device portfolio. About StrykerStryker is a global leader in medical technologies and, together with its custom…

AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA low-dose interferon therapeutics, today announced that its AI Nose has made a significant breakthrough in factory automation with 79% accuracy in detecting 761 samples across 22 different volatile organic compounds (VOCs). This is a remarkable technological advancement in industrial manufacturing safety and smart manufacturing. During its o…

Unique partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems Abbott now has partnerships with four of the largest companies that develop automated insulin delivery systems – offering more choices to people around the world to benefit from connectivity with Libre technology ABBOTT PARK, Ill., Aug. 7, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. The in…

Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical care Now in its second year, the goal of the Innovation Incubator is to share what works with 1,400 health centers providing affordable care for 31+ million ABBOTT PARK, Ill. and BETHESDA, Md., June 20, 2024 /PRNewswire/ -- The global healthcare company Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative. Eight community health centers have been selected to receive funding, expert guidance and training to design and test new solutions to help advance nutrition and improve care in their communities. One in…

400 million people are infected with Dengue every year. 100 million will show symptoms, and 40,000 will die from the disease. As the world’s fastest-growing mosquito-borne viral disease, a coordinated preventative effort is urgently needed to tackle Dengue. You can help by making World Dengue Day (WDD) a reality. Whilst WDD is widely backed and recognised on 15th June by the International Society for Neglected Tropical Diseases (ISNTD), Asian Dengue Voice and Action (ADVA) Group and dengue scientists around the world, it is not yet recognised by the United Nations. WDD would aim to raise public awareness of Dengue and encourage collaboration of scientific research and government disease control policies across the world. Vote in just one click to support the application to make WDD officia…

Abbott's first-of-its-kind i2i™ technology enables synchronized communication between two leadless pacemakers The AVEIR™ DR leadless pacemaker system is roughly one-tenth the size of a traditional pacemaker and smaller than a AAA battery AVEIR DR leadless pacemakers are designed to address the needs of people in Europe living with abnormal heart rhythms and expand treatment options for Europeans ABBOTT PARK, Ill., June 6, 2024 ­­­­— Abbott today announced it has received CE Mark in Europe for the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker that treats people with abnormal or slow heart rhythms. Approximately 49 million people are living with cardiovascular disease in the European Union, and it is estimated that 14.4 million…

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, and Stayhealthy, Inc., a leader in health and wellness technology, are excited to announce a major distribution agreement. This partnership will bring GTG's innovative Multi-Risk Test to a broader audience in the online pharmacy channel across North America, empowering individuals to take control of their health. Stayhealthy is at the forefront of integrating technology with health solutions. The company's mission is to empower, inspire, and give hope to individuals, families, and communities through enhanced technology and a global wellness network. Their FDA-cleared technologies ha…

More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK) The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD ABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep a…

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. are affected by tricuspid regurgitation,1 which can severely impact quality of life Data from the TRILUMINATE™ Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year ABBOTT PARK, Ill., April 2, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgit…